Sentence	entity_1	entity_2	entity_3	entity_4	entity_5	entity_6	entity_7	entity_8	json	split
Examples for such aberrated genes are MGMT, DAPK, p14ARF, p15INK4b, p16INK4a, BRCA1, CDH13 and APAF - 1 ( 17 - 19).	MGMT,38,42,Protein	DAPK,44,48,Protein	p14ARF,50,56,Protein	p15INK4b,58,66,Protein	p16INK4a,68,76,Protein	BRCA1,78,83,Protein	CDH13,85,90,Protein	APAF - 1,95,103,Protein	"[{""token"": ""MGMT"", ""start_span"": 38, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""DAPK"", ""start_span"": 44, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""p14ARF"", ""start_span"": 50, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""p15INK4b"", ""start_span"": 58, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""p16INK4a"", ""start_span"": 68, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""BRCA1"", ""start_span"": 78, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""CDH13"", ""start_span"": 85, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""APAF - 1"", ""start_span"": 95, ""end_span"": 103, ""type"": ""Protein""}]"	train
To this end, we did not detect a significant difference in DNMT ( DNMT1, DNMT3A and DNMT3B) or MBP ( MBD1, MBD2, MBD4 and MeCP) mRNA expression between IRF - 4 - positive and - negative cells ( Figure 5D).	DNMT1,66,71,Protein	DNMT3A,73,79,Protein	DNMT3B,84,90,Protein	MBD1,101,105,Protein	MBD2,107,111,Protein	MBD4,113,117,Protein	MeCP,122,126,Protein	IRF - 4,152,159,Protein	"[{""token"": ""DNMT1"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""DNMT3A"", ""start_span"": 73, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""DNMT3B"", ""start_span"": 84, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""MBD1"", ""start_span"": 101, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""MBD2"", ""start_span"": 107, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""MBD4"", ""start_span"": 113, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""MeCP"", ""start_span"": 122, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""IRF - 4"", ""start_span"": 152, ""end_span"": 159, ""type"": ""Protein""}]"	train
Functionally, LMP1 can rescue CD40 - deficient mice and restore immunoglobulin ( Ig) class switching, most likely because LMP1 recruits similar TRAF molecules, TRAFs 1 / 2 / 3 / 5 and TRAF6, through the C - terminal activation regions 1 and 2 domains, respectively.	LMP1,14,18,Protein	CD40,30,34,Protein	LMP1,122,126,Protein	TRAFs 1,160,167,Protein	2,170,171,Protein	3,174,175,Protein	5,178,179,Protein	TRAF6,184,189,Protein	"[{""token"": ""LMP1"", ""start_span"": 14, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 122, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""TRAFs 1"", ""start_span"": 160, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 170, ""end_span"": 171, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 174, ""end_span"": 175, ""type"": ""Protein""}, {""token"": ""5"", ""start_span"": 178, ""end_span"": 179, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 184, ""end_span"": 189, ""type"": ""Protein""}]"	train
( A and B) Immunoblot analysis of purified B cells ( CD19 +) from the spleens of WT and LMP1 transgenic mice for Akt signaling, probing for ( A) activated pAkt and downstream targets, including inactivated pGSK3alpha / beta, and ( B) activated p - mTOR, and total levels of FoxO1.	CD19,53,57,Protein	LMP1,88,92,Protein	Akt,113,116,Protein	pAkt,155,159,Protein	pGSK3alpha,206,216,Protein	beta,219,223,Protein	p - mTOR,244,252,Protein	FoxO1,274,279,Protein	"[{""token"": ""CD19"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 88, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""pAkt"", ""start_span"": 155, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""pGSK3alpha"", ""start_span"": 206, ""end_span"": 216, ""type"": ""Protein""}, {""token"": ""beta"", ""start_span"": 219, ""end_span"": 223, ""type"": ""Protein""}, {""token"": ""p - mTOR"", ""start_span"": 244, ""end_span"": 252, ""type"": ""Protein""}, {""token"": ""FoxO1"", ""start_span"": 274, ""end_span"": 279, ""type"": ""Protein""}]"	train
Runx3 is required for Eomes and perforin expression, and both Eomes and Runx3 bind at thePrf1locus; in contrast, perforin expression is unaffected in T - bet - deficient cells.	Runx3,0,5,Protein	Eomes,22,27,Protein	perforin,32,40,Protein	Eomes,62,67,Protein	Runx3,72,77,Protein	thePrf1locus,86,98,Protein	perforin,113,121,Protein	T - bet,150,157,Protein	"[{""token"": ""Runx3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 22, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 32, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 72, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""thePrf1locus"", ""start_span"": 86, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 113, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 150, ""end_span"": 157, ""type"": ""Protein""}]"	train
Because ( a) Runx3 appeared necessary for Eomes induction ( Fig. 3 A), ( b) the kinetics of Eomes expression paralleled those of perforin expression ( Fig. 2), and ( c) overexpression of Eo - VP16 in either WT or T - bet - deficient T cells led to an increase in both perforin and IFN - gamma expression ( Fig. 2, B and D), we asked whether CTL differentiation was also potentially regulated by a feed - forward loop involving these same two classes of Runx and T - box transcription factors.	Runx3,13,18,Protein	Eomes,42,47,Protein	Eomes,92,97,Protein	perforin,129,137,Protein	Eo - VP16,187,196,Protein	T - bet,213,220,Protein	perforin,268,276,Protein	IFN - gamma,281,292,Protein	"[{""token"": ""Runx3"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 42, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 92, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 129, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""Eo - VP16"", ""start_span"": 187, ""end_span"": 196, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 213, ""end_span"": 220, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 268, ""end_span"": 276, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 281, ""end_span"": 292, ""type"": ""Protein""}]"	train
Because of the limited number of CD8 + T cells in these mice, and because we saw no difference between Runx3 - / - CD8 + CD4 - SP and CD8 + CD4 + DP cells in our previous experiments, we used total Runx3 - / - CD8 + T cells without further fractionation as recipients for retroviral transduction.	CD8,33,36,Protein	Runx3,103,108,Protein	CD8,115,118,Protein	CD4,121,124,Protein	CD8,134,137,Protein	CD4,140,143,Protein	Runx3,198,203,Protein	CD8,210,213,Protein	"[{""token"": ""CD8"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 103, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 115, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 121, ""end_span"": 124, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 134, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 198, ""end_span"": 203, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 210, ""end_span"": 213, ""type"": ""Protein""}]"	train
Rather, T - bet and Eomes were involved in regulating granzyme B and perforin expression, respectively: up - regulation of T - bet and Eomes mRNA and protein closely preceded up - regulation of Gzmb and Prf1 mRNA and protein, respectively.	T - bet,8,15,Protein	Eomes,20,25,Protein	granzyme B,54,64,Protein	perforin,69,77,Protein	T - bet,123,130,Protein	Eomes,135,140,Protein	Gzmb,194,198,Protein	Prf1,203,207,Protein	"[{""token"": ""T - bet"", ""start_span"": 8, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 20, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""granzyme B"", ""start_span"": 54, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 69, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 123, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 135, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""Gzmb"", ""start_span"": 194, ""end_span"": 198, ""type"": ""Protein""}, {""token"": ""Prf1"", ""start_span"": 203, ""end_span"": 207, ""type"": ""Protein""}]"	train
Because conventional Eomes - deficient mice die before precursor cells can be isolated for bone marrow transfers ( 27) and because T cells conditionally deficient in Eomes have only recently been described ( 9), we were unable to introduce Runx3 into Eomes - deficient CD8 + T cells to test formally whether Eomes cooperated with Runx3 to induce perforin expression.	Eomes,21,26,Protein	Eomes,166,171,Protein	Runx3,240,245,Protein	Eomes,251,256,Protein	CD8,269,272,Protein	Eomes,308,313,Protein	Runx3,330,335,Protein	perforin,346,354,Protein	"[{""token"": ""Eomes"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 166, ""end_span"": 171, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 240, ""end_span"": 245, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 251, ""end_span"": 256, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 269, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 308, ""end_span"": 313, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 330, ""end_span"": 335, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 346, ""end_span"": 354, ""type"": ""Protein""}]"	train
AP - 1 activation requires Fos ( c - Fos, FosB, Fra - 1, Fra - 2) and Jun ( c - Jun, v - Jun, JunB, JunD) through the formation of homo - and hetero - dimers [ 16, 17], and regulates transcription of a broad range of genes involved in immune responses [ 18 - 21].	c - Fos,33,40,Protein	FosB,42,46,Protein	Fra - 1,48,55,Protein	Fra - 2,57,64,Protein	c - Jun,76,83,Protein	v - Jun,85,92,Protein	JunB,94,98,Protein	JunD,100,104,Protein	"[{""token"": ""c - Fos"", ""start_span"": 33, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""FosB"", ""start_span"": 42, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""Fra - 1"", ""start_span"": 48, ""end_span"": 55, ""type"": ""Protein""}, {""token"": ""Fra - 2"", ""start_span"": 57, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 76, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""v - Jun"", ""start_span"": 85, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""JunB"", ""start_span"": 94, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""JunD"", ""start_span"": 100, ""end_span"": 104, ""type"": ""Protein""}]"	train
Material immunoprecipitated with an isotype control antibody ( isotype) or anti - CD40 antibody was examined by Western blotting for CD40, TRAF2, TRAF3, cIAP1, HOIP, IKKalpha / beta, and IKKgamma ( right panels).	CD40,82,86,Protein	TRAF2,139,144,Protein	TRAF3,146,151,Protein	cIAP1,153,158,Protein	HOIP,160,164,Protein	IKKalpha,166,174,Protein	beta,177,181,Protein	IKKgamma,187,195,Protein	"[{""token"": ""CD40"", ""start_span"": 82, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 139, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 146, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""cIAP1"", ""start_span"": 153, ""end_span"": 158, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 160, ""end_span"": 164, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 166, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""beta"", ""start_span"": 177, ""end_span"": 181, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 187, ""end_span"": 195, ""type"": ""Protein""}]"	train
( C) To further evaluate HOIP - dependent recruitment of IKKgamma to CD40, A20. 2J cells or HOIP - deficient ( HOIP - / -) A20. 2J cells were transduced with an empty retroviral vector or a retroviral construct encoding BP epitope - tagged IKKgamma ( noted in the figure as pMIP and IKKgamma, respectively).	HOIP,25,29,Protein	IKKgamma,57,65,Protein	CD40,69,73,Protein	HOIP,92,96,Protein	HOIP,111,115,Protein	IKKgamma,240,248,Protein	pMIP,274,278,Protein	IKKgamma,283,291,Protein	"[{""token"": ""HOIP"", ""start_span"": 25, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 57, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 69, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 92, ""end_span"": 96, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 111, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 240, ""end_span"": 248, ""type"": ""Protein""}, {""token"": ""pMIP"", ""start_span"": 274, ""end_span"": 278, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 283, ""end_span"": 291, ""type"": ""Protein""}]"	train
Hundred nanogram of unspecific siRNA ( control), Sp1 - specific siRNA ( Sp1), Sp3 - specific siRNA ( Sp3) or a mixture of 50 ng Sp1 - specific plus 50 ng Sp3 - specific siRNA ( Sp1 + Sp3) were used.	Sp1,49,52,Protein	Sp1,72,75,Protein	Sp3,78,81,Protein	Sp3,101,104,Protein	Sp1,128,131,Protein	Sp3,154,157,Protein	Sp1,177,180,Protein	Sp3,183,186,Protein	"[{""token"": ""Sp1"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 72, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 78, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 101, ""end_span"": 104, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 128, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 154, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""Sp1"", ""start_span"": 177, ""end_span"": 180, ""type"": ""Protein""}, {""token"": ""Sp3"", ""start_span"": 183, ""end_span"": 186, ""type"": ""Protein""}]"	valid
However, BCR - induced Erk phosphorylation was also reduced in PKD1 / 3 - / - - Flag - PKD3 + B cells ( data not shown) suggesting that reduced BCR levels on the surface of PKD1 / 3 - / - ( and PKD1 / 3 - / - - Flag - PKD3 +) B cells may itself impact on the strength of activation of this specific intracellular signalling pathway.	PKD1,63,67,Protein	3,70,71,Protein	PKD3,87,91,Protein	PKD1,173,177,Protein	3,180,181,Protein	PKD1,194,198,Protein	3,201,202,Protein	PKD3,218,222,Protein	"[{""token"": ""PKD1"", ""start_span"": 63, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 70, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""PKD3"", ""start_span"": 87, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 173, ""end_span"": 177, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 180, ""end_span"": 181, ""type"": ""Protein""}, {""token"": ""PKD1"", ""start_span"": 194, ""end_span"": 198, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 201, ""end_span"": 202, ""type"": ""Protein""}, {""token"": ""PKD3"", ""start_span"": 218, ""end_span"": 222, ""type"": ""Protein""}]"	valid
The IL - 4 + cells were confined to the FOXP3 - cells, as shown for the CD45RO + CD25 -, CD45RO + CD25 +, and CD45RO + CD25 + high cells ( Figure 3B).	IL - 4,4,10,Protein	FOXP3,40,45,Protein	CD45RO,72,78,Protein	CD25,81,85,Protein	CD45RO,89,95,Protein	CD25,98,102,Protein	CD45RO,110,116,Protein	CD25,119,123,Protein	"[{""token"": ""IL - 4"", ""start_span"": 4, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 40, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 72, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 81, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 89, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 98, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 110, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 119, ""end_span"": 123, ""type"": ""Protein""}]"	valid
The IL - 4 - mediated prevention of FOXP3 expression was not caused by interferences of the receptor signaling, because the phosphorylation of SMAD2 or STAT6 was not affected by the addition of IL - 4 and / or TGF - beta, which demonstrates that IL - 4 as well as TGF - beta signaling were functional under these conditions ( Figure 5C).	IL - 4,4,10,Protein	FOXP3,36,41,Protein	SMAD2,143,148,Protein	STAT6,152,157,Protein	IL - 4,194,200,Protein	TGF - beta,210,220,Protein	IL - 4,246,252,Protein	TGF - beta,264,274,Protein	"[{""token"": ""IL - 4"", ""start_span"": 4, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 36, ""end_span"": 41, ""type"": ""Protein""}, {""token"": ""SMAD2"", ""start_span"": 143, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""STAT6"", ""start_span"": 152, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 194, ""end_span"": 200, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 210, ""end_span"": 220, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 246, ""end_span"": 252, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 264, ""end_span"": 274, ""type"": ""Protein""}]"	valid
Although TGF - beta - reduced CD25, IL - 4 expression, and CD25 expression ( Figure 6B), IL - 4 significantly inhibited TGF - beta - mediated induction of FOXP3 in naive T cells driven toward FOXP3 + T cells, as shown by FACS analysis ( Figure 6A).	TGF - beta,9,19,Protein	CD25,30,34,Protein	IL - 4,36,42,Protein	CD25,59,63,Protein	IL - 4,89,95,Protein	TGF - beta,120,130,Protein	FOXP3,155,160,Protein	FOXP3,192,197,Protein	"[{""token"": ""TGF - beta"", ""start_span"": 9, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 30, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 36, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 59, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 89, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 120, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 155, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 192, ""end_span"": 197, ""type"": ""Protein""}]"	valid
Furthermore the TGF - beta - mediated induction of FOXP3 expression was not caused by overgrowth of a CD25 - FOXP3 + minority, since the number of FOXP3 + cells was low / absent in the purified CD4 + CD45RA + T cells ( between 0% and 1%), and the FOXP3 + cells were not confined to the highly divided cells.	TGF - beta,16,26,Protein	FOXP3,51,56,Protein	CD25,102,106,Protein	FOXP3,109,114,Protein	FOXP3,147,152,Protein	CD4,194,197,Protein	CD45RA,200,206,Protein	FOXP3,247,252,Protein	"[{""token"": ""TGF - beta"", ""start_span"": 16, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 109, ""end_span"": 114, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 147, ""end_span"": 152, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 194, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""CD45RA"", ""start_span"": 200, ""end_span"": 206, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 247, ""end_span"": 252, ""type"": ""Protein""}]"	valid
( C) Kinetic analysis of intracellular GATA3 and FOXP3 staining is shown in panel C following exposure of CD4 + CD45RA + T cells to anti - CD3 / 28, IL - 4 and TGF - beta.	GATA3,39,44,Protein	FOXP3,49,54,Protein	CD4,106,109,Protein	CD45RA,112,118,Protein	CD3,139,142,Protein	28,145,147,Protein	IL - 4,149,155,Protein	TGF - beta,160,170,Protein	"[{""token"": ""GATA3"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 49, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 106, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""CD45RA"", ""start_span"": 112, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 139, ""end_span"": 142, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 145, ""end_span"": 147, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 149, ""end_span"": 155, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 160, ""end_span"": 170, ""type"": ""Protein""}]"	valid
Circulating human CD4 + CD25high CD127 - T reg cells significantly expressed higher levels of RUNX3, FOXP3, and TGF - beta mRNA compared with CD4 + CD25 - cells.	CD4,18,21,Protein	CD25high,24,32,Protein	CD127,33,38,Protein	RUNX3,94,99,Protein	FOXP3,101,106,Protein	TGF - beta,112,122,Protein	CD4,142,145,Protein	CD25,148,152,Protein	"[{""token"": ""CD4"", ""start_span"": 18, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""CD25high"", ""start_span"": 24, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""CD127"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 94, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 101, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 112, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 142, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 148, ""end_span"": 152, ""type"": ""Protein""}]"	valid
In contrast, the combination of both TGF - beta and anti - CD2 / 3 / 28 mAbs induced RUNX1 and RUNX3 mRNAs, as well as FOXP3 mRNA, within 48 h in naive CD4 + T cells.	TGF - beta,37,47,Protein	CD2,59,62,Protein	3,65,66,Protein	28,69,71,Protein	RUNX1,85,90,Protein	RUNX3,95,100,Protein	FOXP3,119,124,Protein	CD4,152,155,Protein	"[{""token"": ""TGF - beta"", ""start_span"": 37, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 59, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 65, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 69, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 85, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 95, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 119, ""end_span"": 124, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 152, ""end_span"": 155, ""type"": ""Protein""}]"	valid
To determine whether RUNX1 and RUNX3 are also expressed in human T reg cells in vivo, we isolated peripheral blood CD4 + CD127 - CD25high T reg cells and compared them with CD4 + CD127 + CD25 - T cells.	RUNX1,21,26,Protein	RUNX3,31,36,Protein	CD4,115,118,Protein	CD127,121,126,Protein	CD25high,129,137,Protein	CD4,173,176,Protein	CD127,179,184,Protein	CD25,187,191,Protein	"[{""token"": ""RUNX1"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 31, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 115, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""CD127"", ""start_span"": 121, ""end_span"": 126, ""type"": ""Protein""}, {""token"": ""CD25high"", ""start_span"": 129, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 173, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""CD127"", ""start_span"": 179, ""end_span"": 184, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 187, ""end_span"": 191, ""type"": ""Protein""}]"	valid
For the in vivo Foxp3 conversion assay, naive CD4 + T cells from Cbfb CD4 - cre or control mice ( harboring a Foxp3 - IRES - GFP allele) were adoptively transferred into Rag - deficient mice.	Foxp3,16,21,Protein	CD4,46,49,Protein	Cbfb,65,69,Protein	CD4,70,73,Protein	cre,76,79,Protein	Foxp3,110,115,Protein	GFP,125,128,Protein	Rag,170,173,Protein	"[{""token"": ""Foxp3"", ""start_span"": 16, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 46, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""Cbfb"", ""start_span"": 65, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 70, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""cre"", ""start_span"": 76, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 110, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 125, ""end_span"": 128, ""type"": ""Protein""}, {""token"": ""Rag"", ""start_span"": 170, ""end_span"": 173, ""type"": ""Protein""}]"	valid
To evaluate the effect of overexpression of RUNX1 or RUNX3 on FOXP3 protein levels, CD4 + T cells were preactivated with 2 microg / ml phytohemagglutinin ( Sigma - Aldrich) in serum - free AIM - V medium in the presence of 1 nmol / liter IL - 2 ( Roche) for 12 h, and then transfected with the vector pEGFPN1 containing the RUNX1 or RUNX3 fragment using the Nucleofector system ( Amaxa Biosystems) and the program T - 23.	RUNX1,44,49,Protein	RUNX3,53,58,Protein	FOXP3,62,67,Protein	CD4,84,87,Protein	phytohemagglutinin,135,153,Protein	IL - 2,238,244,Protein	RUNX1,324,329,Protein	RUNX3,333,338,Protein	"[{""token"": ""RUNX1"", ""start_span"": 44, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 53, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 62, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 84, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""phytohemagglutinin"", ""start_span"": 135, ""end_span"": 153, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 238, ""end_span"": 244, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 324, ""end_span"": 329, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 333, ""end_span"": 338, ""type"": ""Protein""}]"	valid
S1 shows the induction of RUNX1, RUNX3, and FOXP3 mRNA in human CD4 + T cells after anti - CD2 / 3 / 28 mAb and TGF - beta stimulation.	RUNX1,26,31,Protein	RUNX3,33,38,Protein	FOXP3,44,49,Protein	CD4,64,67,Protein	CD2,91,94,Protein	3,97,98,Protein	28,101,103,Protein	TGF - beta,112,122,Protein	"[{""token"": ""RUNX1"", ""start_span"": 26, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 44, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 64, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 97, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 101, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 112, ""end_span"": 122, ""type"": ""Protein""}]"	valid
S3 shows the quantification of IL - 4, IL - 5, IL - 10, IL - 13, and IFN - gamma levels in control siRNA transfected or RUNX1 and RUNX3 siRNA transfected human CD4 + T cells.	IL - 4,31,37,Protein	IL - 5,39,45,Protein	IL - 10,47,54,Protein	IL - 13,56,63,Protein	IFN - gamma,69,80,Protein	RUNX1,120,125,Protein	RUNX3,130,135,Protein	CD4,160,163,Protein	"[{""token"": ""IL - 4"", ""start_span"": 31, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 39, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 47, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""IL - 13"", ""start_span"": 56, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 69, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 120, ""end_span"": 125, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 130, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 160, ""end_span"": 163, ""type"": ""Protein""}]"	valid
( B) FOXP3 mRNA induction by anti - CD2 / 3 / 28 mAb and TGF - beta in human naive CD4 + T cells is reduced after siRNA - mediated RUNX1 / 3 knockdown.	FOXP3,5,10,Protein	CD2,36,39,Protein	3,42,43,Protein	28,46,48,Protein	TGF - beta,57,67,Protein	CD4,83,86,Protein	RUNX1,131,136,Protein	3,139,140,Protein	"[{""token"": ""FOXP3"", ""start_span"": 5, ""end_span"": 10, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 36, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 42, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 46, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 57, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 83, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 131, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 139, ""end_span"": 140, ""type"": ""Protein""}]"	valid
Real - time PCR of RNA from human naive CD4 + T cells, transfected with RUNX1 and / or RUNX3 siRNA or with a control siRNA and cultured with anti - CD2 / 3 / 28, TGF - beta and IL - 2.	CD4,40,43,Protein	RUNX1,72,77,Protein	RUNX3,87,92,Protein	CD2,148,151,Protein	3,154,155,Protein	28,158,160,Protein	TGF - beta,162,172,Protein	IL - 2,177,183,Protein	"[{""token"": ""CD4"", ""start_span"": 40, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 72, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 87, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 148, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 154, ""end_span"": 155, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 158, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 162, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 177, ""end_span"": 183, ""type"": ""Protein""}]"	valid
Human naive CD4 + T cells were transfected with RUNX1 and / or RUNX3 siRNA or with a control siRNA and stimulated with anti - CD2 / 3 / 28 and TGF - beta in the presence of IL - 2.	CD4,12,15,Protein	RUNX1,48,53,Protein	RUNX3,63,68,Protein	CD2,126,129,Protein	3,132,133,Protein	28,136,138,Protein	TGF - beta,143,153,Protein	IL - 2,173,179,Protein	"[{""token"": ""CD4"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 48, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 63, ""end_span"": 68, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 126, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 132, ""end_span"": 133, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 136, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 143, ""end_span"": 153, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 173, ""end_span"": 179, ""type"": ""Protein""}]"	valid
Moreover, Tat associating with IkappaB - alpha competed the binding of IkappaB - alpha to p65 in a dose - dependent manner ( Figure 3C, lanes 3 - 5), while Tat R ( 49 - 57) A, which lacked the binding site for IkappaB - alpha, did not associate with IkappaB - alpha and did not compete the binding of IkappaB - alpha to p65 ( Figure 3C, lanes 6 - 8).	Tat,10,13,Protein	IkappaB - alpha,31,46,Protein	IkappaB - alpha,71,86,Protein	p65,90,93,Protein	IkappaB - alpha,210,225,Protein	IkappaB - alpha,250,265,Protein	IkappaB - alpha,301,316,Protein	p65,320,323,Protein	"[{""token"": ""Tat"", ""start_span"": 10, ""end_span"": 13, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 31, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 71, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 90, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 210, ""end_span"": 225, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 250, ""end_span"": 265, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 301, ""end_span"": 316, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 320, ""end_span"": 323, ""type"": ""Protein""}]"	valid
Further evidence of Tat activation of NF - kappaB showed that wild - type Tat, and not the Tat mutants lacking the arginine - or cysteine - rich domains, up - regulated in vivo the expression of a number of NF - kappaB - responsive genes, including MIP - 1alpha, CSF3, LTA, NFKBIA and TLR2.	Tat,20,23,Protein	Tat,74,77,Protein	Tat mutants,91,102,Protein	MIP - 1alpha,249,261,Protein	CSF3,263,267,Protein	LTA,269,272,Protein	NFKBIA,274,280,Protein	TLR2,285,289,Protein	"[{""token"": ""Tat"", ""start_span"": 20, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 74, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""Tat mutants"", ""start_span"": 91, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 249, ""end_span"": 261, ""type"": ""Protein""}, {""token"": ""CSF3"", ""start_span"": 263, ""end_span"": 267, ""type"": ""Protein""}, {""token"": ""LTA"", ""start_span"": 269, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""NFKBIA"", ""start_span"": 274, ""end_span"": 280, ""type"": ""Protein""}, {""token"": ""TLR2"", ""start_span"": 285, ""end_span"": 289, ""type"": ""Protein""}]"	valid
Despite high - level IL - 10R1 expression and constitutive STAT3 activation, IL - 10 - induced tyrosine phosphorylation of STAT3 is suppressed in RA CD4 + T cells, in contrast to normal CD4 + T cells, where STAT3 phosphorylation is dose - dependently inducible by IL - 10.	IL - 10R1,21,30,Protein	STAT3,59,64,Protein	IL - 10,77,84,Protein	STAT3,123,128,Protein	CD4,149,152,Protein	CD4,186,189,Protein	STAT3,207,212,Protein	IL - 10,264,271,Protein	"[{""token"": ""IL - 10R1"", ""start_span"": 21, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 59, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 77, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 123, ""end_span"": 128, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 149, ""end_span"": 152, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 186, ""end_span"": 189, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 207, ""end_span"": 212, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 264, ""end_span"": 271, ""type"": ""Protein""}]"	test
Increased SOCS1 expression in RA CD4 + T cells may therefore be associated with both the impaired responsiveness to IL - 10 and to IL - 10 - mediated STAT3 activation, and defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL - 6.	SOCS1,10,15,Protein	CD4,33,36,Protein	IL - 10,116,123,Protein	IL - 10,131,138,Protein	STAT3,150,155,Protein	SOCS3,182,187,Protein	STAT3,233,238,Protein	IL - 6,271,277,Protein	"[{""token"": ""SOCS1"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 33, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 116, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 131, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 150, ""end_span"": 155, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 182, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 233, ""end_span"": 238, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 271, ""end_span"": 277, ""type"": ""Protein""}]"	test
There is a possibility that SOCS1 induction may be associated with the ability of CD4 + T cells to produce IFN - gamma, because CD4 + T cells from active RA could produce high levels of IFN - gamma in the presence of IL - 10, and because IFN - gamma has been known as a potent inducer of SOCS1 [ 32].	SOCS1,28,33,Protein	CD4,82,85,Protein	IFN - gamma,107,118,Protein	CD4,128,131,Protein	IFN - gamma,186,197,Protein	IL - 10,217,224,Protein	IFN - gamma,238,249,Protein	SOCS1,288,293,Protein	"[{""token"": ""SOCS1"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 107, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 128, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 186, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 217, ""end_span"": 224, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 238, ""end_span"": 249, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 288, ""end_span"": 293, ""type"": ""Protein""}]"	test
Among tested cytokines and chemokines, IL - 15, monocyte chemoattractant protein - 1 and IL - 6 upregulated IL - 17 production ( P < 0. 05), whereas tumor necrosis factor - alpha, IL - 1beta, IL - 18 or transforming growth factor - beta did not.	IL - 15,39,46,Protein	monocyte chemoattractant protein - 1,48,84,Protein	IL - 6,89,95,Protein	IL - 17,108,115,Protein	tumor necrosis factor - alpha,149,178,Protein	IL - 1beta,180,190,Protein	IL - 18,192,199,Protein	transforming growth factor - beta,203,236,Protein	"[{""token"": ""IL - 15"", ""start_span"": 39, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""monocyte chemoattractant protein - 1"", ""start_span"": 48, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 89, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 108, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""tumor necrosis factor - alpha"", ""start_span"": 149, ""end_span"": 178, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 180, ""end_span"": 190, ""type"": ""Protein""}, {""token"": ""IL - 18"", ""start_span"": 192, ""end_span"": 199, ""type"": ""Protein""}, {""token"": ""transforming growth factor - beta"", ""start_span"": 203, ""end_span"": 236, ""type"": ""Protein""}]"	test
Recombinant IL - 17, IL - 18, IL - 15, monocyte chemoattractant protein - 1 ( MCP - 1), macrophage inflammatory protein ( MIP) - 1alpha, MIP - 1beta, IL - 6 and IL - 8 were purchased from R & D systems ( Minneapolis, MN, USA).	IL - 17,12,19,Protein	IL - 18,21,28,Protein	IL - 15,30,37,Protein	monocyte chemoattractant protein - 1,39,75,Protein	MCP - 1,78,85,Protein	MIP - 1beta,137,148,Protein	IL - 6,150,156,Protein	IL - 8,161,167,Protein	"[{""token"": ""IL - 17"", ""start_span"": 12, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""IL - 18"", ""start_span"": 21, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""IL - 15"", ""start_span"": 30, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""monocyte chemoattractant protein - 1"", ""start_span"": 39, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""MCP - 1"", ""start_span"": 78, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""MIP - 1beta"", ""start_span"": 137, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 150, ""end_span"": 156, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 161, ""end_span"": 167, ""type"": ""Protein""}]"	test
Because of the GP - induced band shifts to seven sites from the TNFalpha, IL - 8, IL - 6 and IFNgamma promoters, it could be assumed that GP treatment of human PBMC would lead to production of TNFalpha, IL - 8, IL - 6, IFNgamma and other pro - inflammatory mediators.	TNFalpha,64,72,Protein	IL - 8,74,80,Protein	IL - 6,82,88,Protein	IFNgamma,93,101,Protein	TNFalpha,193,201,Protein	IL - 8,203,209,Protein	IL - 6,211,217,Protein	IFNgamma,219,227,Protein	"[{""token"": ""TNFalpha"", ""start_span"": 64, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 74, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 82, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 93, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 193, ""end_span"": 201, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 203, ""end_span"": 209, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 211, ""end_span"": 217, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 219, ""end_span"": 227, ""type"": ""Protein""}]"	test
ABIN - 1, ABIN - 2 and ABIN - 3 ( also known as TNIP - 1, TNIP - 2, and TNIP - 3) were identified as ubiquitously expressed A20 interacting proteins and were shown to inhibit NF - kappaB activation by TNF and several other inflammatory stimuli upon overexpression.	ABIN - 1,0,8,Protein	ABIN - 2,10,18,Protein	ABIN - 3,23,31,Protein	TNIP - 1,48,56,Protein	TNIP - 2,58,66,Protein	TNIP - 3,72,80,Protein	A20,124,127,Protein	TNF,201,204,Protein	"[{""token"": ""ABIN - 1"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""ABIN - 2"", ""start_span"": 10, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""ABIN - 3"", ""start_span"": 23, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""TNIP - 1"", ""start_span"": 48, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""TNIP - 2"", ""start_span"": 58, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""TNIP - 3"", ""start_span"": 72, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""A20"", ""start_span"": 124, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 201, ""end_span"": 204, ""type"": ""Protein""}]"	test
CYLD expression is markedly upregulated under conditions of RANKL - induced osteoclastogenesis and is recruited to ubiquitinated TRAF6 via the ubiquitin - binding adaptor protein p62 ( also known as sequestosome 1) [ 65], followed by the CYLD - mediated deubiquitination of TRAF6.	CYLD,0,4,Protein	RANKL,60,65,Protein	TRAF6,129,134,Protein	ubiquitin,143,152,Protein	p62,179,182,Protein	sequestosome 1,199,213,Protein	CYLD,238,242,Protein	TRAF6,274,279,Protein	"[{""token"": ""CYLD"", ""start_span"": 0, ""end_span"": 4, ""type"": ""Protein""}, {""token"": ""RANKL"", ""start_span"": 60, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 129, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""ubiquitin"", ""start_span"": 143, ""end_span"": 152, ""type"": ""Protein""}, {""token"": ""p62"", ""start_span"": 179, ""end_span"": 182, ""type"": ""Protein""}, {""token"": ""sequestosome 1"", ""start_span"": 199, ""end_span"": 213, ""type"": ""Protein""}, {""token"": ""CYLD"", ""start_span"": 238, ""end_span"": 242, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 274, ""end_span"": 279, ""type"": ""Protein""}]"	test
Triggering of PRRs induces the production of host proinflammatory cytokines ( e. g. TNF, IL - 6 and IL - 1) and type I interferons ( interferon - alpha ( IFN - alpha) and IFN - beta) through activation of downstream signaling pathways that control various transcription factors such as NF - kappaB, AP - 1, IRF3 and IRF7 [ 1], [ 2].	TNF,84,87,Protein	IL - 6,89,95,Protein	IL - 1,100,106,Protein	interferon - alpha,133,151,Protein	IFN - alpha,154,165,Protein	IFN - beta,171,181,Protein	IRF3,307,311,Protein	IRF7,316,320,Protein	"[{""token"": ""TNF"", ""start_span"": 84, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 89, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""IL - 1"", ""start_span"": 100, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""interferon - alpha"", ""start_span"": 133, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""IFN - alpha"", ""start_span"": 154, ""end_span"": 165, ""type"": ""Protein""}, {""token"": ""IFN - beta"", ""start_span"": 171, ""end_span"": 181, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 307, ""end_span"": 311, ""type"": ""Protein""}, {""token"": ""IRF7"", ""start_span"": 316, ""end_span"": 320, ""type"": ""Protein""}]"	test
Expression and secretion of the proinflammatory cytokines IL - 6 and TNF, the type - I IFN IFNbeta and IFNalpha4 and the chemokines MCP - 1 ( ccl2) and KC ( cxcl1) was significantly higher in IAV infected cells lacking A20 compared to infected wild type cells ( figure 2C and figure S1).	IL - 6,58,64,Protein	TNF,69,72,Protein	IFNbeta,91,98,Protein	IFNalpha4,103,112,Protein	MCP - 1,132,139,Protein	ccl2,142,146,Protein	KC,152,154,Protein	cxcl1,157,162,Protein	"[{""token"": ""IL - 6"", ""start_span"": 58, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 69, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 91, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""IFNalpha4"", ""start_span"": 103, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""MCP - 1"", ""start_span"": 132, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""ccl2"", ""start_span"": 142, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""KC"", ""start_span"": 152, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""cxcl1"", ""start_span"": 157, ""end_span"": 162, ""type"": ""Protein""}]"	test
Unlike the other NFAT proteins ( NFATp, NFATc, NFAT3, and NFAT4), NFAT5 binds DNA as an obligate dimer in a fashion resembling NF - kappaB proteins [ 58], is calcineurin independent, and does not cooperate with the basic region - leucine zipper proteins Fos and Jun in gene activation ( [ 59], [ 60], reviewed in [ 61] - [ 63]).	NFATp,33,38,Protein	NFATc,40,45,Protein	NFAT3,47,52,Protein	NFAT4,58,63,Protein	NFAT5,66,71,Protein	calcineurin,158,169,Protein	Fos,254,257,Protein	Jun,262,265,Protein	"[{""token"": ""NFATp"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""NFATc"", ""start_span"": 40, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""NFAT3"", ""start_span"": 47, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""NFAT4"", ""start_span"": 58, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 66, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""calcineurin"", ""start_span"": 158, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""Fos"", ""start_span"": 254, ""end_span"": 257, ""type"": ""Protein""}, {""token"": ""Jun"", ""start_span"": 262, ""end_span"": 265, ""type"": ""Protein""}]"	test
The first WW domain of WWOX may interact with proteins possessing a PPxY motif ( s) such as AP - 2gamma, p73, ErbB4, Ezrin, SIMPLE, c - Jun, RUNX4, and many others ( Chang et al., 2007; Salah et al., 2012; Su et al., 2012; Figure 1).	WWOX,23,27,Protein	AP - 2gamma,92,103,Protein	p73,105,108,Protein	ErbB4,110,115,Protein	Ezrin,117,122,Protein	SIMPLE,124,130,Protein	c - Jun,132,139,Protein	RUNX4,141,146,Protein	"[{""token"": ""WWOX"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""AP - 2gamma"", ""start_span"": 92, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""p73"", ""start_span"": 105, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""ErbB4"", ""start_span"": 110, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""Ezrin"", ""start_span"": 117, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""SIMPLE"", ""start_span"": 124, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 132, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""RUNX4"", ""start_span"": 141, ""end_span"": 146, ""type"": ""Protein""}]"	test
